Fig. 2

Comparison of median peak eosinophils per high-power field in baseline, post-PPI monotherapy, and post-FED monotherapy in (A) all 22 patients with EoE responsive to PPI monotherapy who trialed FED monotherapy in the retrospective phase of our study, and (B) the 13 patients who had EoE that was histologically responsive to PPI monotherapy and FED monotherapy. A Peak eosinophils per high-power field in baseline (median 47.5, IQR 26.25–83.75) versus post-PPI monotherapy (median 2.5, IQR 0–6), post-FED monotherapy (median 10, IQR 2.25–30). B Peak eosinophils per high-power field in baseline (median 38, IQR 20–85) versus post-PPI monotherapy (median 1, IQR 0–4), post-FED monotherapy (median 6, IQR 1–10). Error bars represent the interquartile range. Paired comparisons were made using the Wilcoxon Signed Rank Test. *** indicates p < 0.001